Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 14/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 11/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 8/20 | 1.00 |
| ▸ | GLA | P06280 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.83 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.83 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.83 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.83 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.83 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.83 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.83 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.80 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.80 |
| ▸ | SLC2A1 | P11166 | 4/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5144149 | 1.00 | ADRB3 (1.00) | ADRB3ADRB2ADRB1GLACYP2D6 | |
| SCHEMBL9006835 | 1.00 | ADRB3 (1.00) | ADRB3ADRB2ADRB1GLACYP2D6 | |
| SCHEMBL5144153 | 1.00 | ADRB3 (1.00) | ADRB3ADRB2ADRB1GLACYP2D6 | |
| SCHEMBL4611391 | 1.00 | ADRB3 (1.00) | ADRB3ADRB2ADRB1GLACYP2D6 | |
| Bromide SCHEMBL29460100 | 0.99 | ADRB3 (0.98) | ADRB3ADRB2ADRB1GLACYP2D6 | |
| Bromide SCHEMBL9317314 | 0.99 | ADRB3 (0.98) | ADRB3ADRB2ADRB1GLACYP2D6 | |
| Bromide SCHEMBL9799484 | 0.99 | ADRB3 (0.98) | ADRB3ADRB2ADRB1GLACYP2D6 | |
| Trifluoroacetic Acid SCHEMBL9318455 | 0.94 | ADRB3 (0.89) | ADRB3ADRB2ADRB1GLACYP2D6 | |
| SCHEMBL9812022 | 0.91 | ADRB3 (0.84) | ADRB3ADRB2ADRB1GLACYP2D6 | |
| SCHEMBL9436811 | 0.91 | ADRB3 (0.84) | ADRB3ADRB2ADRB1GLACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240301022-A1 | GLYCOPROTEINS HAVING LIPID MOBILIZING PROPERTIES AND THERAPEUTIC USES THEREOF | UNIV ASTON (GB) | 2024-09-12 | — | — | US | claimed |
| WO-2022198259-A1 | TREATMENT METHODS FOR PULMONARY ARTERIAL HYPERTENSION | THE HEART RESEARCH INSTITUTE LTD (AU) | 2022-09-29 | — | — | WO | claimed |
| JP-6293664-A | — | — | None | — | — | JP | disclosed |
| US-20260077012-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF NEURODEGENERATIVE DISEASES | EPITRACKER INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-12427179-B2 | Compositions and methods for diagnosis and treatment of neurodegenerative diseases | Epitracker, Inc. (US) | 2025-09-30 | — | — | US | disclosed |
| US-20250262170-A1 | COMBINATIONS OF BETA 2-ADRENERGIC RECEPTOR AGONISTS AND BETA 3-ADRENERGIC RECEPTOR AGONISTS, AND MEDICAL USES THEREOF | ATROGI AB (SE) | 2025-08-21 | — | — | US | disclosed |
| EP-4590287-A1 | COMPOSITIONS AND METHODS FOR IMPROVING GUT PERMEABILITY | Brightseed, Inc. (US) | 2025-07-30 | — | — | EP | disclosed |
| US-20250205182-A1 | COMPOSITIONS AND METHODS FOR IMPROVING GUT PERMEABILITY | BRIGHTSEED, INC. | 2025-06-26 | — | — | US | disclosed |
| US-20250134955-A1 | TARGETED OESOPHAGEAL ADMINISTRATION OF ZN-ALPHA2-GLYCOPROTEINS (ZAG), METHODS AND FORMULATIONS THEREOF | ASTON UNIVERSITY (GB) | 2025-05-01 | — | — | US | disclosed |
| EP-4525833-A2 | VETERINARY PHARMACEUTICAL FORMULATIONS | Increvet, Inc. (US) | 2025-03-26 | — | — | EP | disclosed |
| EP-4511014-A1 | COMBINATIONS OF BETA 2-ADRENERGIC RECEPTOR AGONISTS AND BETA 3-ADRENERGIC RECEPTOR AGONISTS, AND MEDICAL USES THEREOF | Atrogi AB (SE) | 2025-02-26 | — | — | EP | disclosed |
| US-20220151957-A1 | BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS | ANJI PHARMACEUTICALS INC. | 2022-05-19 | — | — | US | disclosed |
| WO-2022098572-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF CONDITIONS RELATED TO THE QUALITY OF AGING AND LONGEVITY | Epitracker, Inc. (US) | 2022-05-12 | — | — | WO | disclosed |
| EP-3971178-A1 | AMINOQUINOLINE DERIVATIVES AND USES THEREOF | The McLean Hospital Corporation (US) | 2022-03-23 | — | — | EP | disclosed |
| US-20220054499-A1 | SMALL MOLECULES FOR MOUSE SATELLITE CELL PROLIFERATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2022-02-24 | — | — | US | disclosed |
| US-7217706-B2 | Propanolamine derivatives | ASTELLAS PHARMA INC. (JP) | 2007-05-15 | — | — | US | disclosed |
| EP-1382333-A2 | Use of beta 3 adrenergic receptor agonists in the treatment of dysuria | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-01-21 | — | — | EP | disclosed |
| US-6495546-B1 | SUCH AS 1-(N-BENZYL-N-(3-METHOXY-6,7,8,9-TETRAHYDRO-5H-BENZO-CYCLOHEPTEN-6-YL)AMINO)-3-PHENOXY-2-PROPANOL; ADRENERGIC RECEPTOR AGONISTS; ANTIULCEROUS, LIPOLYTIC, ANTIURINARY INCONTINENCE AND ANTIPOLLAKIURIA ACTIVITIES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-12-17 | — | — | US | disclosed |
| US-20020120148-A1 | Propanolamine derivatives | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2002-08-29 | — | — | US | disclosed |
| JP-H06293664-A | NEW PHARMACEUTICAL USE OF BETA3-ADRENERGIC AGENT | FUJISAWA PHARMACEUT CO LTD | 1994-10-21 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250262170-A1 | COMBINATIONS OF BETA 2-ADRENERGIC RECEPTOR AGONISTS AND BETA 3-ADRENERGIC RECEPTOR AGONISTS, AND MEDICAL USES THEREOF | ADRB2, ADRB3, ADRB1 | ADRB3 2/4885ADRB2 1/4885ADRB1 3/4885 |
| US-20260077012-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF NEURODEGENERATIVE DISEASES | CD4, COL2A1, MMP1 | ADRB3 1713/4885ADRB2 2486/4885ADRB1 1355/4885 |
| US-20220054499-A1 | SMALL MOLECULES FOR MOUSE SATELLITE CELL PROLIFERATION | MKI67, MYLK2, MYH2 | ADRB3 3611/4885ADRB2 3615/4885ADRB1 3241/4885 |
| US-20250205182-A1 | COMPOSITIONS AND METHODS FOR IMPROVING GUT PERMEABILITY | FABP2, VIP, SI | ADRB3 2442/4885ADRB2 2344/4885ADRB1 2098/4885 |
| US-20220151957-A1 | BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS | SLC5A2, SLC5A1, GPR119 | ADRB3 1759/4885ADRB2 3376/4885ADRB1 2915/4885 |
| US-20020120148-A1 | Propanolamine derivatives | AMY2A, PNMT, PNLIP | ADRB3 12/4885ADRB2 7/4885ADRB1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.